Bullish indicating open at $55-$60, IPO prices at $37
ANN ARBOR, MI—Russell Kevin Klass, the Senior Vice President of Sales at Zomedica Corp. (AMEX:ZOM), recently purchased a significant amount of the company’s common stock. According to a recent SEC filing, Klass acquired 699,980 shares at a price of $0.07 per share on March 17, 2025. This transaction amounted to a total value of $48,998. According to InvestingPro analysis, the stock is currently trading in oversold territory, with a strong balance sheet showing more cash than debt.
Following this acquisition, Klass holds a total of 3,200,030 shares in Zomedica, reflecting his continued confidence in the company’s future prospects. Zomedica, based in Ann Arbor, Michigan, operates in the pharmaceutical preparations industry.
In other recent news, Zomedica Pharmaceuticals (NYSE:ZOM) Corp reported a revenue of $7.9 million for the fourth quarter of 2024, marking an 8% year-over-year increase. Despite a net loss of $7.2 million, the company maintained a strong cash position with $71.4 million in liquidity and achieved a gross margin of 70.3%, which exceeded their target range. The company also recorded a full-year revenue of $27.3 million, which was a record high. Zomedica’s recent delisting from the NYSE American Exchange led to its transition to the OTCQB market, a move that management attributes to share price issues rather than company performance. Analysts have noted that Zomedica’s strong cash position and strategic focus on the veterinary market support its growth prospects. The company is actively exploring options to address its share price and is planning to engage investors through monthly webinars. Additionally, Zomedica is focused on expanding its presence in the equine market and international territories, aiming to reach a cash flow breakeven at a $50 million run rate.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.